Fruquintinib (Elunate)
Jump to navigation
Jump to search
Mechanism of action
VEGFR inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2018-09: Approved for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). (Based on FRESCO)
Also known as
- Code name: HMPL-013
- Brand name: Elunate